Compass Pathways Stock

Compass Pathways Debt

The Debt of Compass Pathways (CMPS) as of Sep 3, 2026 is 33.74 M USD. In the previous year, Debt was 30.17 M USD — a change of 11.86% (higher).

Debt

33.74 MUSD

YoY

11.86%

Last updated:

In 2026, Compass Pathways's total debt was 33.74 M USD, a 11.86% change from the 30.17 M USD total debt recorded in the previous year.

The Compass Pathways Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
0.00 USD
Jan 1, 2019
21.10 M USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
28.76 M USD
Jan 1, 2024
30.17 M USD
Jan 1, 2025
33.74 M USD
The Compass Pathways Debt history
YEARDebtYoY
33.74 MUSD+11.86%
30.17 MUSD+4.90%
28.76 MUSD
0.00USD
0.00USD
0.00USD-100.00%
21.10 MUSD
0.00USD
Access this data via the Eulerpool API

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Debt Details

Understanding Compass Pathways's Debt Structure

Compass Pathways's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Compass Pathways's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Compass Pathways’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Compass Pathways’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Compass Pathways stock

Debt of Compass Pathways is 33.74 M USD in 2026.

Debt of Compass Pathways changed from 30.17 M USD to 33.74 M USD, representing a 11.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Compass Pathways historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Compass Pathways

All Key Metrics — Compass Pathways